Page 479 - Petelin, Ana, in Helena Skočir. 2020. Ur. Raziskovanje za znanje, znanje za zdravje. Zbornik prispevkov z recenzijo. Koper: Založba Univerze na Primorskem.
P. 479
organizacija prevozov za te bolnike dobro poskrbljena. Z raziskavo smo vanesa pintar topolovec, edvard jakšič, mojca dreisinger
tudi ugotovili, da posamezniki menijo, da o svoji bolezni ne vedo prav ve-
liko, kar medicinskim sestram daje možnost dodatnih aktivnosti na področ-
ju poučevanja in zdravstveno-vzgojnega dela. Če bolnik aktivno sodeluje pri
zdravljenju, mora poznati bolezen, namen kelacijske terapije, možne stranske
učinke zdravil in koristi kelacije, kar pa lahko skupaj dosežemo z dobro komu-
nikacijo s celotnim zdravstvenim timom.
Literatura
BOLTON MAGGS, P., in COHEN, H., 2012. Annual SHOT Report 2011. Manchester: SHOT.
BRITISH COMMITTEE FOR STANDARDS IN HAEMATOLOGY. 2009. Guideline on the adminis-
tration of blood components.
DREYFUS, F., 2008. The deleterious effects of iron overload in patients with myelo-
dysplastic syndromes. Blood Rev, 22 (Suppl 2): 29-34. Pridobljeno 18.6.2019 s https://
doi.org/10.1185/03007990802565867
ECKES ELLEN, J., 2011. Chelation therapy for iron overload: nursing practice implications.
J Infus Nurs, 34 (6): 374–380.
KOŠNIK, M., in ŠTAJER, D., 2018. Interna medicina. Ljubljana. Medicinska fakulteta, Sloven-
sko zdravniško društvo. Peta izdaja: 1167 – 1170.
LYLE, L., in HIROSE, A., 2018. Iron overload in myelodysplastic syndromes: pathophysio-
logy, consequences, diagnosis, and treatment. Journal of the advanced practitioner in
oncology, 9 (4): 392-405.
MALCOVATO, L., GIOVANNI DELLAPORTA, M., PASCUTTO, C., INVERNIZZI, R., BONI, M.,
PASSAMONTI TRAVAGLINO, E., PASSAMONTI, F., ARCAINI, L., MAFFIOLI, M., BERNASCO-
NI, P., LAZZARINO, M., in CAZZOLA, M., 2005. Prognostic factors and life expectancy
in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical
decision making. Journal of Clinical Oncology, 23 (30): 7594–7603.
MAST, A., E., in FIELD. J.,J., 2012. Iron chelation therapy in patients with transfusion-depen-
dent myelodysplastic syndrome. Transfusion. 52 (10): 2078-2080.
MLAKAR, U., 2010. Smernice za odkrivanje in zdravljenje mielo displastičnih sindromov
pri odraslih. Zdravstveni Vestnik 79: 455- 464.
MLAKAR, U., 2017. Mielodisplastični sindrom – vodnik za bolnike. Ljubljana. Slovensko zdru-
ženje bolnikov z limfomom in levkemijo – Dopolnjen ponatis.
MOUKALLED NOUR, M., FUAD, A., RASSI, E., TEMRAZ, N. S., in TAHER A. T., 2018. Iron over-
load in patients with myelodysplastic syndromes: An updated overview. Cancer, 124
(20): 3979-3989.
NEUKIRCHEN, J., FOX, F., KÜNDGEN, A., NACHTKAMP, K., STRUPP, C., HAAS, R., GERMING,
U., in GATTERMANN, N., 2012. Improved survival in MDS patients receiving iron che-
lation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS
registry. Leukemia Research, 36 (8):1067–1070. Pridobljeno 18.6.2019 s https://doi.or�-
g/10.1016/j.leukres.2012.04.006
NEUKIRCHEN, J., SCHOONEN, M. W., STRUPP, C., GATTERMANN, N., AUL, C., HAAS, R., in
GERMING U., 2011. Incidence and prevalence of myelodysplastic syndromes: Data
from the Dusseldorf MDS-registry. Leukemia Research. 35 (12):1591-1596. Pridobljeno
18.6.2019 s : https://doi.org/10.1016/j.leukres.2011.06.001
NOVARTIS., 2016. Jemanje zdravila Exjade – Priročnik za bolnika (deferasiroks).
477
tudi ugotovili, da posamezniki menijo, da o svoji bolezni ne vedo prav ve-
liko, kar medicinskim sestram daje možnost dodatnih aktivnosti na področ-
ju poučevanja in zdravstveno-vzgojnega dela. Če bolnik aktivno sodeluje pri
zdravljenju, mora poznati bolezen, namen kelacijske terapije, možne stranske
učinke zdravil in koristi kelacije, kar pa lahko skupaj dosežemo z dobro komu-
nikacijo s celotnim zdravstvenim timom.
Literatura
BOLTON MAGGS, P., in COHEN, H., 2012. Annual SHOT Report 2011. Manchester: SHOT.
BRITISH COMMITTEE FOR STANDARDS IN HAEMATOLOGY. 2009. Guideline on the adminis-
tration of blood components.
DREYFUS, F., 2008. The deleterious effects of iron overload in patients with myelo-
dysplastic syndromes. Blood Rev, 22 (Suppl 2): 29-34. Pridobljeno 18.6.2019 s https://
doi.org/10.1185/03007990802565867
ECKES ELLEN, J., 2011. Chelation therapy for iron overload: nursing practice implications.
J Infus Nurs, 34 (6): 374–380.
KOŠNIK, M., in ŠTAJER, D., 2018. Interna medicina. Ljubljana. Medicinska fakulteta, Sloven-
sko zdravniško društvo. Peta izdaja: 1167 – 1170.
LYLE, L., in HIROSE, A., 2018. Iron overload in myelodysplastic syndromes: pathophysio-
logy, consequences, diagnosis, and treatment. Journal of the advanced practitioner in
oncology, 9 (4): 392-405.
MALCOVATO, L., GIOVANNI DELLAPORTA, M., PASCUTTO, C., INVERNIZZI, R., BONI, M.,
PASSAMONTI TRAVAGLINO, E., PASSAMONTI, F., ARCAINI, L., MAFFIOLI, M., BERNASCO-
NI, P., LAZZARINO, M., in CAZZOLA, M., 2005. Prognostic factors and life expectancy
in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical
decision making. Journal of Clinical Oncology, 23 (30): 7594–7603.
MAST, A., E., in FIELD. J.,J., 2012. Iron chelation therapy in patients with transfusion-depen-
dent myelodysplastic syndrome. Transfusion. 52 (10): 2078-2080.
MLAKAR, U., 2010. Smernice za odkrivanje in zdravljenje mielo displastičnih sindromov
pri odraslih. Zdravstveni Vestnik 79: 455- 464.
MLAKAR, U., 2017. Mielodisplastični sindrom – vodnik za bolnike. Ljubljana. Slovensko zdru-
ženje bolnikov z limfomom in levkemijo – Dopolnjen ponatis.
MOUKALLED NOUR, M., FUAD, A., RASSI, E., TEMRAZ, N. S., in TAHER A. T., 2018. Iron over-
load in patients with myelodysplastic syndromes: An updated overview. Cancer, 124
(20): 3979-3989.
NEUKIRCHEN, J., FOX, F., KÜNDGEN, A., NACHTKAMP, K., STRUPP, C., HAAS, R., GERMING,
U., in GATTERMANN, N., 2012. Improved survival in MDS patients receiving iron che-
lation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS
registry. Leukemia Research, 36 (8):1067–1070. Pridobljeno 18.6.2019 s https://doi.or�-
g/10.1016/j.leukres.2012.04.006
NEUKIRCHEN, J., SCHOONEN, M. W., STRUPP, C., GATTERMANN, N., AUL, C., HAAS, R., in
GERMING U., 2011. Incidence and prevalence of myelodysplastic syndromes: Data
from the Dusseldorf MDS-registry. Leukemia Research. 35 (12):1591-1596. Pridobljeno
18.6.2019 s : https://doi.org/10.1016/j.leukres.2011.06.001
NOVARTIS., 2016. Jemanje zdravila Exjade – Priročnik za bolnika (deferasiroks).
477
